NICE has identified NHS England as funding Gilead's CAR T cell therapy

's CAR T cell therapy Yescarta will be available to some adults with lymphoma on the NHS.The National Institute for Health and Care Excellence says treatment can be funded through the Cancer Drugs Foundation for adult patients with recurring or recurring diffuse large B-cell lymphoma or primary vertical large B-cell lymphoma, two invasive subtypes of non-Hodgkin's lymphoma.Yescarta (axicabtagene-ciloleucel) will be available to those who do not respond after two or more rounds of chemotherapy or relapse after a stem cell transplant.the institute initially rejected the drug as too expensive, but a subsequent confidential commercial deal between NHS England and Gilead Group Kite increased its potential cost-effectiveness."As we prepare to publish our long-term plans for the NHS, this constructive and rapid negotiation shows how the NHS is leading the way by ensuring that patients in England are among the first in the world to benefit from this promising treatment," said John Stewart, director of NHS England's professional committee.in England, about 200 people a year will be eligible for Yescarta, a service that will be rolled out in seven hospitals across the country.NICE said NHS England was working closely with the sites to "ensure that clinical, technical and operational requirements are in place to provide this new and complex treatment."Meindert Boysen, director of nice health technology assessment centre, said: "It is good to see that NHS England is preparing to offer CAR T cell therapy as soon as possible and we hope that people will start treatment as soon as possible. 's final positive guidance is an important milestone for adult patients with invasive non-Hodgkin's lymphoma (NHL), who may not have effective treatment options and therefore have only a few months to live. For the first time, these patients will be able to receive CAR T therapy on the NHS," said Hilary Hutton-Squire, managing director of Gilead Sciences UK and Ireland. We will now continue to work closely with NHS England to prepare services to deliver this treatment to the patients most in need across the country as quickly as possible. "(This web article) is